Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery.

The PALACROS research program was formally launched in Amsterdam this week. It brings together leading European hospitals, researchers, patient organisations, and industry partners to improve treatment for patients with locally advanced pancreatic cancer.

Argent BioPharma has recast itself as an immune science company. In an update to shareholders, it said it will now focus its resources and research on inflammatory disease after licensing CannEpil to a global partner.

NeuroScientific Biopharmaceuticals has announced that US regulators have largely endorsed its plans for a Phase 2 trial of a stem cell therapy in people with Crohn's disease who have not responded to existing treatments.

A new generation of Australian life sciences innovation will take the stage on the Gold Coast this month, with AusBiotech announcing the 2026 participants in its Early-Stage Innovation Forum.

An experimental treatment developed by Syntara improved movement in people at high risk of developing Parkinson's disease, and the benefit lasted three months after treatment stopped, according to new results from a Phase 2 trial.

Perth-based company PYC Therapeutics will take early human data on its polycystic kidney disease drug to the American Society of Nephrology conference in Denver on 22 October.

Clarity Pharmaceuticals has reached its recruitment target for the main group of the expansion phase of its SECuRE trial, and says it is already planning a registrational Phase 3 study of its copper isotope therapy for advanced prostate cancer.

An Australian company has taken one of the country's top design honours for a machine built to solve one of healthcare's most stubborn cleaning problems.

Average pay for chief executives of Australia's largest listed health care and biotechnology companies rose for a second consecutive year in 2026, while average pay at the smallest companies fell, according to a new benchmarking report.

CSL has agreed to pay Alentis Therapeutics US$355 million upfront in an exclusive deal to jointly develop and promote lixudebart, an experimental antibody that could become the first in a new class of treatments for people with rare kidney and liver diseases.

Tetratherix says the US Food and Drug Administration has accepted the core of its application to sell Tegenix, its bone regeneration product.

The board said talks with prospective robotics and defence partners have convinced it that the sensor business is worth more than its established clinical, sport and workplace markets suggest.

Citing the Australian Institute of Health and Welfare, BCAL says 48 per cent of women aged 50 to 74 skip routine breast screening. "Most cancers are still found once symptoms appear, when treatment options are narrower and costlier," the presentation says.

The United States Food and Drug Administration has granted Telix Pharmaceuticals Fast Track designation for its BiPASS program. The decision could shorten the path to market for a scan designed to help men avoid prostate biopsies they may not need.

Paradigm Biopharmaceuticals has entered voluntary administration. The Melbourne drug developer made the move after an interim result halted its Phase 3 trial, and now hopes to restructure its debts while assessing what the trial data can still offer.

Dr Bremer said he was taking over at a pivotal moment. "Neurizon has established a strong foundation around NUZ-001, with an advanced clinical program and an international network spanning clinical development, regulatory, manufacturing and scientific capabilities," he said.

Chief executive Gary Phillips said the expansion would strengthen the results. "We are pleased with the strong engagement from participants and clinical sites in the SNT-9465 Phase 1b study."